Form 4: Rapport Therapeutics CSO Reports Stock Transactions

Rapport Therapeutics' Chief Scientific Officer, David Bredt, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• David Bredt, Chief Scientific Officer of Rapport Therapeutics, Inc., reported changes in his beneficial ownership of common stock.
• On December 31, 2025, 18,000 shares of common stock were acquired due to the vesting of performance-based restricted stock units (PSUs).
• These PSUs were granted on December 4, 2024, and vested after specified performance criteria were met as of December 31, 2025.
• Concurrently, 6,567 shares were sold on December 31, 2025, at a weighted average price of $30.0499 per share to cover tax withholding obligations.
• Following these transactions, David Bredt directly beneficially owns 404,075 shares of Rapport Therapeutics common stock.

Sentiment

Score: 7

Explanation: The vesting of performance-based units is a positive indicator of company performance meeting set criteria. The subsequent sale for tax purposes is a neutral, non-discretionary event. The overall sentiment is moderately positive due to the performance achievement.

Positives

• The vesting of 18,000 performance-based restricted stock units indicates that specified performance criteria were met by the company as of December 31, 2025.
• The Chief Scientific Officer's continued significant direct beneficial ownership of 404,075 shares aligns his interests with shareholders.

Negatives

• The sale of 6,567 shares, while for tax withholding, reduces the direct ownership slightly.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market risks associated with holding equity.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. The reported transactions occurred on December 31, 2025, and are historical events from the perspective of this filing.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all publicly traded industries. It reflects an executive's compensation structure and tax obligations rather than broader industry trends or competitive positioning.

Comparison to Industry Standards

• Insider transactions like PSU vesting and subsequent tax-related sales are standard compensation practices in the biotechnology and pharmaceutical industries, similar to those observed at companies like Moderna, Pfizer, or Biogen.
• The sale to cover tax obligations is a common, non-discretionary event and does not typically signal a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: The vesting of performance-based units suggests the company met certain internal performance targets, which could be viewed positively. The Chief Scientific Officer's continued significant ownership aligns his interests with shareholders.
• Employees: The compensation structure involving PSUs is a common incentive for executives, potentially motivating performance.

Next Steps

• No specific future actions or milestones are mentioned in this filing beyond the reported transactions.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation and tax obligations. The vesting of performance-based units is a positive signal regarding internal performance metrics being met. However, the filing does not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Vesting, Restricted Stock Units, PSUs, Chief Scientific Officer, David Bredt, Beneficial Ownership